Recipharm is a minority investor in binx health
Recipharm and binx health have announced a long-term manufacturing agreement for the supply of single use cartridges for the binx io platform with supply of single use cartridges commencing immediately.
The agreement facilitates the bringing to market of a diagnostics platform, reportedly capable of providing almost instantaneous results to both patients and clinicians for the diagnosis of chlamydia and gonorrhoea. Recipharm will supply cartridges from the Kings Lynn operation in the United Kingdom.
Jeff Luber, CEO binx health, said: “I am very pleased we are further consolidating our relationship with Recipharm and look forward to developing this further with additional capacity. The opportunities for the binx io platform are enormous and it is important to us that we have a reliable partner”.
Keyvan Djamarani, CEO of Bespak by Recipharm said: “We are excited to be part of this project and to be supporting the binx io platform. Point of Care (POC) testing is an under-exploited segment which will only grow and Recipharm sees this opportunity as a strategically important entry into this interesting business segment and highly complementary to the Bespak by Recipharm offering”.